Instem plc First Contract Win for Instem Clinical (3502I)
July 02 2013 - 2:00AM
UK Regulatory
TIDMINS
RNS Number : 3502I
Instem plc
02 July 2013
2 July 2013
Embargoed for 07:00
Instem plc
("Instem", the "Company" or the "Group")
First Contract Win for Instem Clinical
Instem plc (AIM: INS.L), a leading provider of IT applications
to the global early development healthcare market, is pleased to
announce its first contract win for its newly acquired ALPHADAS
software. The contract consists of a high six-figure GBP perpetual
licence plus implementation services, with ongoing annual support
and maintenance.
ALPHADAS,the market leading, e-source data capture ("EDC")
system and site automation software suite for early phase clinical
studies, has been selected by a UK-based global leader in the
provision of specialisedclinical services. ALPHADAS is now offered
by Instem Clinical, formerly Logos Technologies, which was acquired
by Instem in May 2013.
Replacing a more traditional 'form based' EDC system, ALPHADAS
was selected for its ability to deliver an immediate and
significant return on investment within the client's highly complex
studies. ALPHADAS sources data direct from instrumentation, removes
errors at source, tracks samples from collection to dispatch and
enables critical real time data review. Further efficiencies are
also delivered by ALPHADAS through its ability to track study
subjects throughout the recruitment process, staff resourcing and
site management and the provision of a fully visible audit
trail.
Phil Reason, CEO of Instem plc, commented, "We are delighted to
be able to announce a significant contract win for Instem Clinical,
so quickly after it was established following the acquisition of
Logos in May this year. A leader in their field and experiencing
significant growth, the new client is currently working with some
of the world's foremost pharmaceutical and research companies. This
is a clear demonstration of the quality of the ALPHADAS software
and the opportunity to expand Instem's market to early clinical
studies."
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Aubrey Powell
Joe Stroud
Newgate Threadneedle +44 (0) 20 7653 9850
Caroline Evans-Jones
Fiona Conroy
About Instem plc
Instem is a leading supplier of IT applications to the early
development healthcare market delivering compelling solutions for
data collection, management and analysis across the R&D
continuum. Instem applications are used by customers worldwide,
meeting the rapidlyexpanding needs of life science and healthcare
organisations for data-driven decision making leading to safer,
more effective products.
Instem's portfolio of software solutions increases client
productivity by automating study-related processes while offering
the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem supports its clients through full service offices in the
United States, United Kingdom and China with additional locations
in India and a full service distributor based in Japan.
To learn more about Instem solutions and its mission, please
visit www.instem.com or its investor centre
http://investors.instem.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTUGUAWMUPWPGG
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024